Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Revenue Growth Expected to Reach $3.46 Billion by 2030 with 9.3% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Between 2026 And 2030?
The market for chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing has experienced significant expansion in recent times. This market is projected to expand from $2.19 billion in 2025 to $2.43 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 10.9%. Historically, this growth can be ascribed to factors such as enhanced screening of sexually active individuals, the development of laboratory testing facilities, the widespread use of NAAT and PCR technologies, increased understanding of co-infection dangers, and the proliferation of diagnostic laboratories.
The market size for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing is poised for significant expansion in the upcoming years. This market is projected to reach $3.47 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.3%. The forecasted growth can be linked to several factors, including increasing investments in decentralized testing, rising adoption of home-based diagnostics, the expansion of automated laboratory platforms, a growing emphasis on early STI detection, and an increasing demand for integrated CT/NG testing solutions. Concurrently, major trends expected during this period involve the increasing adoption of multiplex STI testing panels, a rising demand for rapid point-of-care testing, the growing use of self-testing kits, the expansion of high-sensitivity molecular assays, and enhanced integration of laboratory automation.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The anticipated expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market is fueled by the growing prevalence of sexually transmitted infections (STIs). STIs are defined as illnesses resulting from bacterial, viral, or parasitic infections transferable via sexual contact. Factors contributing to the surge in STI rates include inadequate comprehensive sex education, heightened sexual activity, associated stigma, and accessibility challenges. chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing serves to identify and manage STIs through facilitating early detection, effective treatment, and transmission prevention. Illustratively, the Minority HIV/AIDS Fund (MHAF), a US government agency, reported in October 2025 that an estimated 39.9 million people globally were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, an increase from prior years. Consequently, the expanding volume of sexually transmitted infections is a key impetus for the growth of the CTNG testing market.
Which Market Segments Are Examined In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Study?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests
What Key Trends Are Influencing The Development Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Leading firms within the chlamydia market are prioritizing the creation of novel solutions, like the broadening of Point-of-Care Molecular Diagnostics, to facilitate quicker, more precise detection at the point of care and enhance prompt treatment results. The expansion of point-of-care molecular diagnostics signifies the wider integration of rapid, on-site molecular testing capabilities, enabling instantaneous identification of infections like chlamydia without dependence on central lab facilities. An example is F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, which, in January 2025, obtained FDA 510(k) clearance and a CLIA waiver for its cobas® liat molecular tests, engineered for diagnosing sexually transmitted infections (STIs) directly at the point of care. These specific tests incorporate multiplex assay panels capable of identifying and distinguishing various STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a sole patient specimen, providing results within 20 minutes or less.
Who Are The Primary Competitors In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies operating in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc, PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc, Meridian Bioscience Inc, Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd, Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd, NG Biotech
Read the full chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report here:
What Are The Leading Geographic Regions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2025. The regions covered in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Browse Through More Reports Similar to the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2026, By The Business Research Company
Chlamydia Infection Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Chlamydia Infection Diagnostics And Therapeutics Global Market Report
Sexually Transmitted Infections Stis Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
